多形膠芽腫治療市場：タイプ別、エンドユーザー別-2025-2030年の世界予測

多形膠芽腫治療市場は、2023年に31億1,000万米ドルと評価され、2024年には33億6,000万米ドルに達すると予測され、CAGR 8.17％で成長し、2030年には53億9,000万米ドルに達すると予測されています。

多形膠芽腫（GBM）は、高度な治療戦略を必要とする侵攻性の脳腫瘍です。GBM治療市場は、標的薬、免疫療法、精密医療などの革新的治療に対する需要によって定義されます。GBMに関連する高い死亡率と再発率を考えると、これらの治療は極めて重要であり、継続的な研究開発が必要です。現在の治療用途は、病院環境から専門のがん治療センターまで広がっています。最終用途の範囲には、ヘルスケアプロバイダー、患者、研究機関が含まれ、GBM患者の生存率と生活の質の向上に焦点を当てています。成長要因としては、バイオテクノロジーの進歩、腫瘍学研究への投資の増加、新規ドラッグデリバリーシステムの開発などが挙げられます。製薬企業と研究機関の共同研究の増加、個別化治療アプローチのための遺伝子・分子プロファイリングの探求、臨床試験の拡大など、ビジネスチャンスは豊富にあります。しかし、治療費の高さ、認知度の低さ、早期発見方法の不十分さなどの課題もあります。さらに、厳しい規制の枠組みは、新しい治療の承認や市場参入を遅らせる可能性があります。技術革新の可能性がある治療分野としては、マルチターゲット治療の開発、血液脳関門透過技術の強化、治療成績の予測モデリングにAIを活用することなどが挙げられます。腫瘍微小環境相互作用や神経腫瘍学バイオマーカーなどの分野の調査により、重要な知見が得られる可能性があります。GBM治療市場の性質は、急速な技術進歩と効果的なソリューションの緊急の必要性によって特徴付けられる、非常に競争的でダイナミックなものです。企業は、戦略的パートナーシップ、学際的研究への参加、新たな科学的知見に適応する柔軟性の維持に注力すべきです。全体として、個別化医療、広範な臨床試験、強固なデータ分析に注力することで、事業の成長を促進し、治療効果を向上させることができると思われます。

市場力学：急速に進化する多形膠芽腫治療市場の主要市場インサイトを公開

多形膠芽腫治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 脳・神経疾患の有病率の上昇
  • 脳疾患や腫瘍の早期発見と治療に対する意識の高まり
  • 各国におけるヘルスケアインフラの改善
• 市場抑制要因
  • 多形膠芽腫の治療に伴う高コストと合併症
• 市場機会
  • 臨床研究を促進するための投資の増加
  • 多形性膠芽腫を治療する新しい技術の出現
• 市場の課題
  • 多形膠芽腫治療に関連する償還の問題と厳しい規制遵守

ポーターのファイブフォース：多形膠芽腫治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、多形膠芽腫治療市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：多形膠芽腫治療市場における外部からの影響の把握

外部マクロ環境要因は、多形膠芽腫治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析多形膠芽腫治療市場における競合情勢の把握

多形膠芽腫治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス多形膠芽腫治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、多形膠芽腫治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨多形膠芽腫治療市場における成功への道筋を描く

多形膠芽腫治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 脳および神経疾患の罹患率の上昇
    • 脳疾患や腫瘍の早期発見と治療に対する意識の高まり
    • 経済全体にわたるヘルスケアインフラの改善
  • 抑制要因
    • 多形性膠芽腫の治療に伴う高額な費用と合併症
  • 機会
    • 臨床調査を促進するための投資の増加
    • 多形性膠芽腫の治療における新たな技術の出現
  • 課題
    • 多形膠芽腫治療に関連する償還問題と厳格な規制遵守
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 多形膠芽腫治療市場：タイプ別

• 化学療法
• 複合療法
• 医薬品
• 放射線治療
• 手術
• 標的療法

第7章 多形膠芽腫治療市場：エンドユーザー別

• 病院
• 専門センター

第8章 南北アメリカの多形膠芽腫治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の多形膠芽腫治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの多形膠芽腫治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AIVITA Biomedical, Inc.
• Angiochem Inc.
• Avant Immunotherapeutics, Inc.
• Bayer AG
• Chimerix Inc.
• Daiichi Sankyo Company, Limited
• Diffusion Pharmaceuticals Inc.
• DNAtrix, Inc.
• Eisai Co., Ltd.
• F. Hoffmann-La Roche Ltd
• Karyopharm Therapeutics Inc.
• Kazia Therapeutics Limited
• Lineage Cell Therapeutics, Inc.
• Merck & Co. Inc.
• Moleculin Biotech, Inc.
• Novocure GmbH
• OncoSynergy, Inc.
• Pfizer Inc.
• Sapience Therapeutics, Inc.
• SonALAsense
• Sumitomo Dainippon Pharma Oncology, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• VBI Vaccines Inc.
• VBL Therapeutics

LIST OF FIGURES

• FIGURE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GLIOBLASTOMA MULTIFORME TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINED MODALITY THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 24. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 36. CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 38. INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 40. INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 42. JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 44. MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 46. PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 48. SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 50. SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 52. TAIWAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. TAIWAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 54. THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 56. VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 61. DENMARK GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. DENMARK GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 63. EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 65. FINLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. FINLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 67. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 69. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 71. ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 73. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 75. NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 77. NIGERIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. NIGERIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 79. NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 81. POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 83. QATAR GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. QATAR GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 85. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 87. SAUDI ARABIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SAUDI ARABIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 91. SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 93. SWEDEN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. SWEDEN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 95. SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 97. TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 99. UNITED ARAB EMIRATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. UNITED ARAB EMIRATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 101. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 103. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 104. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Glioblastoma Multiforme Treatment Market was valued at USD 3.11 billion in 2023, expected to reach USD 3.36 billion in 2024, and is projected to grow at a CAGR of 8.17%, to USD 5.39 billion by 2030.

Glioblastoma Multiforme (GBM) is an aggressive form of brain cancer requiring advanced treatment strategies. The market for GBM treatments is defined by the demand for innovative therapies, such as targeted drugs, immunotherapies, and precision medicine. These treatments are crucial, given the high mortality and recurrence rates associated with GBM, necessitating ongoing research and development. Current applications extend from hospital settings to specialized cancer treatment centers. The end-use scope includes healthcare providers, patients, and research institutions focusing on improved survival rates and quality of life for GBM patients. Influencing growth factors include advancements in biotechnology, increasing investment in oncology research, and the development of novel drug delivery systems. Opportunities abound with rising collaborations between pharmaceutical companies and research institutions, the exploration of genetic and molecular profiling for personalized treatment approaches, and the expansion of clinical trials. However, the market faces challenges such as the high cost of treatment, limited awareness, and insufficient early detection methodologies. Additionally, stringent regulatory frameworks can delay approval and market entry for new treatments. Potential areas of innovation include the development of multi-targeted therapies, enhancing blood-brain barrier penetration techniques, and utilizing AI for predictive modeling in treatment outcomes. Research in areas such as tumor microenvironment interactions and neuro-oncology biomarkers could unlock significant insights. The nature of the GBM treatment market is highly competitive and dynamic, characterized by rapid technological advancements and the urgent need for effective solutions. Companies should focus on strategic partnerships, engaging in interdisciplinary research, and maintaining flexibility to adapt to new scientific findings. Overall, a focus on personalized medicine, expansive clinical trials, and robust data analytics could propel business growth and improve treatment efficacy.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glioblastoma Multiforme Treatment Market

The Glioblastoma Multiforme Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of brain and neurological diseases
  • Growing awareness of early detection and treatments related to brain disorders and tumors
  • Improved healthcare infrastructure across economies
• Market Restraints
  • High cost and complications associated with glioblastoma multiforme treatments
• Market Opportunities
  • Increasing investments to foster clinical research
  • Emerging new techniques to treat glioblastoma multiforme
• Market Challenges
  • Reimbursement issues and stringent regulatory compliances associated with glioblastoma multiforme treatment

Porter's Five Forces: A Strategic Tool for Navigating the Glioblastoma Multiforme Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glioblastoma Multiforme Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glioblastoma Multiforme Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glioblastoma Multiforme Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glioblastoma Multiforme Treatment Market

A detailed market share analysis in the Glioblastoma Multiforme Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glioblastoma Multiforme Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glioblastoma Multiforme Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glioblastoma Multiforme Treatment Market

A strategic analysis of the Glioblastoma Multiforme Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glioblastoma Multiforme Treatment Market, highlighting leading vendors and their innovative profiles. These include AIVITA Biomedical, Inc., Angiochem Inc., Avant Immunotherapeutics, Inc., Bayer AG, Chimerix Inc., Daiichi Sankyo Company, Limited, Diffusion Pharmaceuticals Inc., DNAtrix, Inc., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc., Kazia Therapeutics Limited, Lineage Cell Therapeutics, Inc., Merck & Co. Inc., Moleculin Biotech, Inc., Novocure GmbH, OncoSynergy, Inc., Pfizer Inc., Sapience Therapeutics, Inc., SonALAsense, Sumitomo Dainippon Pharma Oncology, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., VBI Vaccines Inc., and VBL Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Glioblastoma Multiforme Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Chemotherapy, Combined Modality Therapy, Medications, Radiation Therapy, Surgery, and Targeted Therapy.
• Based on End-Users, market is studied across Hospitals and Speciality Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of brain and neurological diseases
    • 5.1.1.2. Growing awareness of early detection and treatments related to brain disorders and tumors
    • 5.1.1.3. Improved healthcare infrastructure across economies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost and complications associated with glioblastoma multiforme treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing investments to foster clinical research
    • 5.1.3.2. Emerging new techniques to treat glioblastoma multiforme
  • 5.1.4. Challenges
    • 5.1.4.1. Reimbursement issues and stringent regulatory compliances associated with glioblastoma multiforme treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Glioblastoma Multiforme Treatment Market, by Type

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Combined Modality Therapy
• 6.4. Medications
• 6.5. Radiation Therapy
• 6.6. Surgery
• 6.7. Targeted Therapy

7. Glioblastoma Multiforme Treatment Market, by End-Users

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Speciality Centers

8. Americas Glioblastoma Multiforme Treatment Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Glioblastoma Multiforme Treatment Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Glioblastoma Multiforme Treatment Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AIVITA Biomedical, Inc.
• 2. Angiochem Inc.
• 3. Avant Immunotherapeutics, Inc.
• 4. Bayer AG
• 5. Chimerix Inc.
• 6. Daiichi Sankyo Company, Limited
• 7. Diffusion Pharmaceuticals Inc.
• 8. DNAtrix, Inc.
• 9. Eisai Co., Ltd.
• 10. F. Hoffmann-La Roche Ltd
• 11. Karyopharm Therapeutics Inc.
• 12. Kazia Therapeutics Limited
• 13. Lineage Cell Therapeutics, Inc.
• 14. Merck & Co. Inc.
• 15. Moleculin Biotech, Inc.
• 16. Novocure GmbH
• 17. OncoSynergy, Inc.
• 18. Pfizer Inc.
• 19. Sapience Therapeutics, Inc.
• 20. SonALAsense
• 21. Sumitomo Dainippon Pharma Oncology, Inc.
• 22. Sun Pharmaceutical Industries Ltd.
• 23. Teva Pharmaceutical Industries Ltd.
• 24. VBI Vaccines Inc.
• 25. VBL Therapeutics